Bristol Myers Squibb (BMY): financials, SEC filings and peers

Bristol Myers Squibb (BMY) is a pharmaceuticals company in the Health Care sector of the S&P 500, headquartered in New York City, New York.

It was founded in 1989 and joined the S&P 500 on March 4, 1957.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Pharmaceutical Preparations”.

Bristol Myers Squibb at a glance

Revenue (12 months): $49.2B
Revenue growth: +3.1%
Operating margin: 27.7%
Net income (12 months): $9.3B
Free cash flow (12 months): $11.4B
Cash: $8.7B
Debt: $43.9B
Diluted EPS (12 months): $4.54

Twelve months to June 30, 2026, from the 10-Q filed July 30, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, Bristol Myers Squibb reported revenue of $49.2 billion, about the same as a year earlier (+3.1%).

Its operating margin was 27.7%, up 9.8 percentage points from a year earlier: for every $100 of sales, about $28 was left as operating profit.

Net income was $9.3 billion (18.9% of revenue), 83.8% higher than a year earlier.

Operating cash flow was $12.8 billion and capital spending $1.3 billion, leaving free cash flow of $11.4 billion (23.3% of revenue).

At the end of the period it held $8.7 billion in cash and $43.9 billion in debt, a net debt position of $35.2 billion.

Five-year trend

Revenue went from $42.5 billion in fiscal 2020 to $48.2 billion in fiscal 2025, about 2.5% a year.
Free cash flow was positive in each of the last 6 fiscal years.
Bristol Myers Squibb reported a net loss in 2 of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$46.4B	$46.2B	$45.0B	$48.3B	$48.2B
Revenue growth	9.1%	-0.5%	-2.5%	7.3%	-0.2%
Operating margin	—	—	—	—	—
Net income	$7.0B	$6.3B	$8.0B	−$8.9B	$7.1B
Free cash flow	$15.2B	$11.9B	$12.7B	$13.9B	$12.8B
Diluted EPS	$3.12	$2.95	$3.86	$-4.41	$3.46

Fiscal years as reported in Bristol Myers Squibb’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed July 30, 2026 — quarterly report
8-K filed July 30, 2026 — Earnings results; Regulation FD disclosure
8-K filed May 8, 2026 — Shareholder vote results
10-Q filed April 30, 2026 — quarterly report
8-K filed April 30, 2026 — Earnings results; Regulation FD disclosure
10-K filed February 11, 2026 — annual report
8-K filed February 5, 2026 — Earnings results; Regulation FD disclosure
8-K filed January 12, 2026 — Regulation FD disclosure

All Bristol Myers Squibb filings on SEC EDGAR

Companies like Bristol Myers Squibb

Other S&P 500 companies in Pharmaceuticals:

More from Health Care

All 60 Health Care companies →

Questions about Bristol Myers Squibb

Is Bristol Myers Squibb's revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $49.2 billion, up 3.1% from a year earlier, according to its SEC filings.

Is Bristol Myers Squibb profitable?

Yes. It earned $9.3 billion in net income over the twelve months to June 30, 2026, a net margin of 18.9%.

Does Bristol Myers Squibb have more cash or more debt?

At June 30, 2026 it had $8.7 billion in cash and $43.9 billion in debt, so more debt than cash.

When did Bristol Myers Squibb last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on July 30, 2026.

Which companies are similar to Bristol Myers Squibb?

In the S&P 500, Bristol Myers Squibb is grouped in Pharmaceuticals within the Health Care sector. Johnson & Johnson (JNJ), Lilly (Eli) (LLY), Merck & Co. (MRK), Pfizer (PFE), Viatris (VTRS) are in the same group.

Understand the numbers

Source: Bristol Myers Squibb’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.